Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Recent advances in maximum safe glioma resection have included the introduction of a host of visualization techniques to complement intraoperative white-light imaging of tumors. However, barriers to the effective use of these techniques within the central nervous system remain. In the healthy brain, the blood-brain barrier ensures the stability of the sensitive internal environment of the brain by protecting the active functions of the central nervous system and preventing the invasion of microorganisms and toxins. Brain tumors, however, often cause degradation and dysfunction of this barrier, resulting in a heterogeneous increase in vascular permeability throughout the tumor mass and outside it. Thus, the characteristics of both the blood-brain and blood-brain tumor barriers hinder the vascular delivery of a variety of therapeutic substances to brain tumors. Recent developments in fluorescent visualization of brain tumors offer improvements in the extent of maximal safe resection, but many of these fluorescent agents must reach the tumor via the vasculature. As a result, these fluorescence-guided resection techniques are often limited by the extent of vascular permeability in tumor regions and by the failure to stain the full volume of tumor tissue. In this review, we describe the structure and function of both the blood-brain and blood-brain tumor barriers in the context of the current state of fluorescence-guided imaging of brain tumors. We discuss features of currently used techniques for fluorescence-guided brain tumor resection, with an emphasis on their interactions with the blood-brain and blood-tumor barriers. Finally, we discuss a selection of novel preclinical techniques that have the potential to enhance the delivery of therapeutics to brain tumors in spite of the barrier properties of the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Synthesis and Characterization of Monodisperse Nanocrystals and Close-Packed Nanocrystal Assemblies
Murray, C. B., Kagan, C. R., & Bawendi, M. G. (2000) · Annual Review of Materials Science · doi:10.1146/annurev.matsci.30.1.545 · Cited by 4,353
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437 · cited 1×
“Altogether, these elements form a so-called neurovascular unit, capable of responding dynamically to local changes in physiology and environment (38, 41, 42).”
BackgroundBlood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Pericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Development, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376 · cited 1×
“Passive Delivery Passive delivery through the intact BBTB is challenging, as most small lipophilic drugs that could diffuse through the BBB are not targeted and exhibit toxicity in high doses, and most hydrophilic molecules do not pass through the narrow TJs of the BBB (140, 141).”
BackgroundPericytes are required for blood–brain barrier integrity during embryogenesis
Daneman, R., Zhou, L., Kebede, A. A., & Barres, B. A. (2010) · Nature · doi:10.1038/nature09513 · Cited by 2,128
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670 · cited 5×
“expressed at the BBB are diverse, including the transferrin receptor (29), neonatal Fc receptor (30, 31), and low-density lipoprotein receptor 1 (LRP1) (25).”
BackgroundInfluentialSaraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
A rapid and robust method for single cell chromatin accessibility profiling
Chen, X., Miragaia, R. J., Natarajan, K. N., & Teichmann, S. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07771-0 · Cited by 1,147
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954 · cited 1×
“The focused ultrasound induces stable cavitation in the bubbles as they pass through the ultrasound field, mediating precise and transient disruption of the BBB via the downregulation of TJ proteins (82), suppression of P-glycoprotein expression (161), and facilitation of pinocytosis (162).”
BackgroundBlood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841
Quantum dots in imaging, drug delivery and sensor applications
Matea, C., Mocan, T., Tabaran, F., Pop, T., Mosteanu, O., Puia, C., Iancu, C., & Mocan, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s138624 · Cited by 666
Luissint, A.-C., Artus, C., Glacial, F., Ganeshamoorthy, K., & Couraud, P.-O. (2012) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-9-23 · Cited by 654 · cited 1×
“The severity of barrier compromise ranges significantly, from critical disruption comparable to the vasculature in solid, non-brain neoplasms to mild compromise found in neurodegenerative disease, stroke, diabetes, and obesity, among other pathologies (18, 21, 43).”
BackgroundDemeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557
Glioblastoma: defining tumor niches
Hambardzumyan, D., & Bergers, G. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.009 · Cited by 522 · cited 1×
“Alternatively, infiltrating glioma cells may be shielded by an intact BBB from intravascularly administered diagnostic and therapeutic agents (72, 73).”
BackgroundCSF, blood-brain barrier, and brain drug delivery
Pardridge, W. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1171315 · Cited by 508
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Biosynthesis of heme in mammals
Ajioka, R. S., Phillips, J. D., & Kushner, J. P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.05.005 · Cited by 493
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
5-ALA and FDA Approval for Glioma Surgery
Hadjipanayis, C. G., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03098-y · Cited by 338
Krishna, V., Sammartino, F., & Rezai, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3129 · Cited by 289
Phototheranostics: Active Targeting of Orthotopic Glioma Using Biomimetic Proteolipid Nanoparticles
Jia, Y., Wang, X., Hu, D., Wang, P., Liu, Q., Zhang, X., Jiang, J., Liu, X., Sheng, Z., Liu, B., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06556 · Cited by 211
di Biase, L., Falato, E., & Di Lazzaro, V. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00549 · Cited by 166
Pardridge, W. M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1042364 · Cited by 159
Yang, X., Palasuberniam, P., Kraus, D., & Chen, B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025865 · Cited by 158
Liu, W., Baer, M. R., Bowman, M. J., Pera, P., Zheng, X., Morgan, J., Pandey, R. A., & Oseroff, A. R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1599 · Cited by 136
Candela, P., Gosselet, F., Miller, F., Buee-Scherrer, V., Torpier, G., Cecchelli, R., & Fenart, L. (2008) · Endothelium · doi:10.1080/10623320802487759 · Cited by 117
Palasuberniam, P., Yang, X., Kraus, D., Jones, P., Myers, K. A., & Chen, B. (2015) · Scientific Reports · doi:10.1038/srep13298 · Cited by 89
Dalton, J. T., Yates, C. R., Yin, D., Straughn, A., Marcus, S. L., Golub, A. L., & Meyer, M. C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.507 · Cited by 75
Visualization technologies for 5-ALA-based fluorescence-guided surgeries
Wei, L., Roberts, D. W., Sanai, N., & Liu, J. T. C. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03077-9 · Cited by 67
Kaneko, S., Suero Molina, E., Ewelt, C., Warneke, N., & Stummer, W. (2019) · Neurosurgery · doi:10.1093/neuros/nyz129 · Cited by 56
The Hydroxypyridinone Iron Chelator CP94 Can Enhance PpIX‐induced PDT of Cultured Human Glioma Cells
Blake, E., & Curnow, A. (2010) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2010.00770.x · Cited by 51
Quantitative Modulation of PpIX Fluorescence and Improved Glioma Visualization
Reinert, M., Piffaretti, D., Wilzbach, M., Hauger, C., Guckler, R., Marchi, F., & D'Angelo, M. L. (2019) · Frontiers in Surgery · doi:10.3389/fsurg.2019.00041 · Cited by 22
Cited by
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Enhancing brain tumor detection in MRI images using YOLO-NeuroBoost model
Chen, A., Lin, D., & Gao, Q. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1445882 · Cited by 35
Metadata
- Authors
- Belykh, E., Shaffer, K. V., Lin, C., Byvaltsev, V. A., Preul, M. C., & Chen, L.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-06-05
- Volume
- 10
- Pages
- 739-739
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3033721615
- Cited by
- 191
- References
- 40
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.